Michael J. Soileau

799 total citations
22 papers, 236 citations indexed

About

Michael J. Soileau is a scholar working on Neurology, Cognitive Neuroscience and Psychiatry and Mental health. According to data from OpenAlex, Michael J. Soileau has authored 22 papers receiving a total of 236 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Neurology, 6 papers in Cognitive Neuroscience and 3 papers in Psychiatry and Mental health. Recurrent topics in Michael J. Soileau's work include Parkinson's Disease Mechanisms and Treatments (18 papers), Neurological disorders and treatments (14 papers) and Autism Spectrum Disorder Research (5 papers). Michael J. Soileau is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (18 papers), Neurological disorders and treatments (14 papers) and Autism Spectrum Disorder Research (5 papers). Michael J. Soileau collaborates with scholars based in United States, Canada and Denmark. Michael J. Soileau's co-authors include Parag G. Patil, Carol Persad, Jennifer L. Taylor, David G. Standaert, Jason Aldred, Kelvin L. Chou, Irene Litvan, Hui Zheng, Thomas Kimber and Meredith Spindler and has published in prestigious journals such as Neurology, The Lancet Neurology and Movement Disorders.

In The Last Decade

Michael J. Soileau

20 papers receiving 233 citations

Peers

Michael J. Soileau
T.H. Tsoi China
Márk Harmat Hungary
Francesca Graziano Italy
Massimo Pederzoli Italy
Rajan Prakash United States
Claire Join-Lambert France
Milan Grofik Slovakia
Mario Coletti Moja Italy
Praween Lolekha Thailand
Ryo Sato Japan
T.H. Tsoi China
Michael J. Soileau
Citations per year, relative to Michael J. Soileau Michael J. Soileau (= 1×) peers T.H. Tsoi

Countries citing papers authored by Michael J. Soileau

Since Specialization
Citations

This map shows the geographic impact of Michael J. Soileau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Soileau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Soileau more than expected).

Fields of papers citing papers by Michael J. Soileau

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Soileau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Soileau. The network helps show where Michael J. Soileau may publish in the future.

Co-authorship network of co-authors of Michael J. Soileau

This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Soileau. A scholar is included among the top collaborators of Michael J. Soileau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Soileau. Michael J. Soileau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Aldred, Jason, Tove Henriksen, Martin Bouchard, et al.. (2025). Treatment patterns with long-term foslevodopa/foscarbidopa use in Parkinson’s disease. Parkinsonism & Related Disorders. 134. 107598–107598. 1 indexed citations
2.
Jimenez‐Shahed, Joohi, Irene A. Malaty, Michael J. Soileau, et al.. (2025). Association of patient characteristics, social drivers of health, and geographic location on access to device-aided therapies among medicare beneficiaries with advanced Parkinson's disease. Parkinsonism & Related Disorders. 133. 107322–107322. 1 indexed citations
3.
Soileau, Michael J., Rajeev Kumar, Pavnit Kukreja, et al.. (2025). Patients’ experience with and perspectives on long-term use of continuous subcutaneous infusion of foslevodopa/foscarbidopa in Parkinson’s disease. Journal of Neurology. 272(6). 416–416. 1 indexed citations
4.
Aldred, Jason, Manon Bouchard, Juan Carlos Martínez‐Castrillo, et al.. (2025). Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease. Movement Disorders Clinical Practice. 13(1). 181–190.
5.
Aldred, Jason, Tove Henriksen, Martin Bouchard, et al.. (2024). Efficacy and safety of foslevodopa/foscarbidopa continuous subcutaneous infusion administered as monotherapy in patients with Parkinson’s disease. Parkinsonism & Related Disorders. 122. 106128–106128. 1 indexed citations
6.
7.
Soileau, Michael J., Jason Aldred, Pavnit Kukreja, et al.. (2024). Living with Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa for Symptom Management in Advanced Parkinson’s Disease: A Patient Experience Study (P9-3.006). Neurology. 102(7_supplement_1). 1 indexed citations
8.
Pahwa, Rajesh, Aristide Merola, Michael J. Soileau, et al.. (2023). Cost‐Effectiveness of Carbidopa‐Levodopa Enteral Suspension for Advanced Parkinson's Disease in the United States. Movement Disorders. 38(12). 2308–2312. 2 indexed citations
9.
10.
Antonini, Angelo, Rajesh Pahwa, Per Odin, et al.. (2022). Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson’s Disease: Real-World Evidence From G7 Countries. Neurology and Therapy. 11(1). 303–318. 10 indexed citations
11.
Malaty, Irene A., Pablo Martínez‐Martín, К. Ray Chaudhuri, et al.. (2022). Does the 5–2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5–2-1-positive patients in 7 countries. BMC Neurology. 22(1). 35–35. 24 indexed citations
12.
Soileau, Michael J., Jason Aldred, Nahome Fisseha, et al.. (2022). Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial. The Lancet Neurology. 21(12). 1099–1109. 93 indexed citations
13.
14.
15.
Fung, Victor S.C., et al.. (2021). 24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical Recommendations. CNS Drugs. 35(2). 137–149. 20 indexed citations
16.
Pahwa, Rajesh, Elizabeth Peckham, Winona Tse, et al.. (2020). Symptomatic Relief in Essential Tremor with Home Use of Non-Invasive Neuromodulation Therapy (435). Neurology. 94(15_supplement). 1 indexed citations
17.
Benge, Jared F., et al.. (2017). Factor structure of the Montreal Cognitive Assessment items in a sample with early Parkinson's disease. Parkinsonism & Related Disorders. 41. 104–108. 7 indexed citations
18.
Cooper, Rachel, et al.. (2017). The Everyday Cognition Scale in Parkinson's Disease. Baylor University Medical Center Proceedings. 30(3). 265–267. 4 indexed citations
19.
Soileau, Michael J., et al.. (2016). Placement of the Abbvie Peg-J Tube for the Treatment of Parkinson's Disease in the Interventional Radiology Suite. Baylor University Medical Center Proceedings. 29(4). 420–422. 6 indexed citations
20.
Hallevi, Hen, Oleg Chernyshev, Ramy El Khoury, et al.. (2011). Intracranial Atherosclerosis Is Associated with Progression of Neurological Deficit in Subcortical Stroke. Cerebrovascular Diseases. 33(1). 64–68. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T.H. Tsoi Breakdown of academic impact, for papers by Márk Harmat Breakdown of academic impact, for papers by Francesca Graziano Breakdown of academic impact, for papers by Massimo Pederzoli Breakdown of academic impact, for papers by Rajan Prakash Breakdown of academic impact, for papers by Claire Join-Lambert Breakdown of academic impact, for papers by Milan Grofik Breakdown of academic impact, for papers by Mario Coletti Moja Breakdown of academic impact, for papers by Praween Lolekha Breakdown of academic impact, for papers by Ryo Sato
Rankless by CCL
2026